|
Therapeutic Area/ Name of Product |
Name of grantee |
Environmental and Health Risk Management Plan (EHRMP) |
|
Expansion of the Center for BioPharma Analysis CBA to increase and enhance service portfolio |
ENTREPRENEURSHIP DEVELOPMENT CENTER (Venture Center) |
|
|
SASTRA University |
SASTRA University |
|
|
A cellular and molecular assay platform for the assessment of vaccine and biopharmaceutical candidates. |
THSTI NCR |
|
|
Validation of production of Epidermal growth factor EGF, Basic fibroblast growth factor bFGF, Insulin-like growth factor IGF-1 and Platelet derived growth factor - BB PDGF-BB using recombinant E. coli clones and scale up to 100L level. |
HiMedia |
|
|
Expansion of existing services and establishment of adventitious viruses testing facility at National Immunogenicity and Biologics Evaluation Center, IRSHA, Pune |
Interactive Research School for Health Affairs(IRSHA)* |
|
|
Enhancement of functionalities with SaaS based approach to offer affordable LIMS and ELN, integration with chromatography systems, automate data transfer from instruments, incorporate DMS and QMS functionalities and scale up for commercialization |
Lab Iconics |
|
|
Phase-III : A prospective, double- blind, parallel arm, comparative study to determine the efficacy and safety of Romiplostim Biosimilar manufactured by Levim Biotech with Nplate manufactured by Amgen in patients with chronic-immune- thrombocytopenia |
Levim Biotech LLP |
|
|
Pre-clinical studies of developed Biosimilar Golimumab Candidate GMB0317B1 |
GeNext Genomics Pvt Ltd |
|
|
Scale-up and analytical similarity demonstration of Pegloticase biosimilar to address unmet medical need in India |
BYCUS THERAPEUTICS |
|
|
INstrong: Stability & Toxicology studies of a Novel Thermostable- Insulin formulation |
LAMARK BIOTECH |
|
|
Pre-clinical Testing of Indigenously Developed Cisplatin Nano-formulation |
Exocan Healthcare Technologies Private Limited |
|